ClinicalTrials.gg
RecruitingNCT07022002Updated Aug 3, 2025

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

A Phase 2 interventional study of SSGJ-705 and PD-1/L1 inhibitor combined with chemotherapy in Locally Advanced, Recurrent or Metastatic Malignancies, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Primary conditionNeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
340
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.

Read the detailed description

This study includes 2 Parts: Part 1 (705 monotherapy for advanced gastric cancer and breast cancer that have failed standard treatment), and Part 2 (705 in combination with chemotherapy for previously untreated advanced gastric cancer and lung cancer).

02

Conditions studied

  • Locally Advanced, Recurrent or Metastatic Malignancies

Browse trials for

Keywords

  • advanced malignancies
03

In context

Neoplasms Reclassified

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 340 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Shenyang Sunshine Pharmaceutical Co., LTD. is the lead sponsor of 40 studies on the registry; 22 are open to participants now.

Compared within Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and/or females over age 18.
  • and/or cytologically documented local advanced or non-Small Cell Lung Cancer(NSCLC),Breast Cancer(BC)or Gastric/Gastroesophageal Junction Cancer (G/GEJC).
  • (ECOG) performance status of 0-1.
  • Expected survival >3 months.
  • Signed form.

Exclusion criteria

Exclusion Criteria:

  • Any remaining adverse events (AEs) > grade 1 from prior anti-tumor treatment as per (CTCAE) v5. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.
  • Pregnant or nursing women or women/men who are ready to give birth.
  • symptomatic central nervous system .
  • Allergy to other antibody drugs or any in the study drugs.
  • Inadequate organ or bone marrow function.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    Part 1

    advanced gastric cancer and breast cancer that have failed standard treatment

    Drug: SSGJ-705

  • Experimental
    Part 2

    previously untreated advanced gastric cancer and lung cancer

    Drug: PD-1/L1 inhibitor combined with chemotherapy · Drug: SSGJ-705 combined with chemotherapy

Interventions

  • anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody

  • DrugPD-1/L1 inhibitor combined with chemotherapy

    Immune checkpoint inhibitors

  • DrugSSGJ-705 combined with chemotherapy

    Drug page: Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705

    anti-PD-1 and anti-HER2 bispecifc antibody

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The primary efficacy end point

    Time frame: 12 months

  2. Incidence of Treatment-Emergent Adverse Events

    The primary safety end point

    Time frame: 12 months

  3. Severity of Treatment-Emergent Adverse Events

    The primary safety end point

    Time frame: 12 months

Secondary outcomes

  1. Progression-Free-Survival (PFS)

    The secondary efficacy end point

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 17 months is below that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 12, 2027
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07022002
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jul 30, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 12, 2027 (estimated)
Last update
Aug 3, 2025

Study contacts

Jieer Ying, M.D
Contact
hzyingjieer@163.com
86-13858195803
Meifang Zheng, M.D.
Contact
794998553@qq.com
86-15258894828

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705

Start the discussion